Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application.
Level 5 - mechanism / opinion, no new human data
Animal experimental study
What was done
Rats subjected to a gastrocnemius muscle complex crush injury received BPC 157 (intraperitoneally or locally as a cream) and/or 6alpha-methylprednisolone (intraperitoneally). Interventions were administered either as a single dose immediately after injury (sacrifice at 2 hours) or once daily until evaluation at days 1, 2, 4, 7, and 14. Muscle healing was assessed functionally, macroscopically, and histologically.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. Qualitatively, untreated control animals showed limited recovery, and 6alpha-methylprednisolone markedly aggravated healing. BPC 157 administered systemically or topically reportedly accelerated muscle healing, restored full function, and reversed corticosteroid-impaired healing across all assessment intervals (2 hours to 14 days) by functional, macroscopic, and histological criteria.
Why it matters
This study suggests that BPC 157 may promote skeletal muscle repair and counteract corticosteroid-induced healing deficits in preclinical models.
Limits
This is an animal study in rats with unproven generalizability to human clinical outcomes. The abstract provides no sample size (n), specific peptide dosages, quantitative data, or statistical significance metrics. Long-term outcomes beyond 14 days were not evaluated.
Cited by
- supports BPC-157 administration counteracts corticosteroid-induced impairment of wound healing in animal models.